LA
PROK icon

LM Advisors’s ProKidney PROK Stock Holding History

LM Advisors’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-127
Closed -$226 – 590
2023
Q4 		$226 Buy
+127
New +$272 ﹤0.01% 720

Other funds holding PROK

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BU
Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LM Advisors's PROK Position: Q1 2024 in Review

LM Advisors sold out of ProKidney (PROK) in Q1 2024, closing a stake of 127 shares — an estimated $226 sold.

LM Advisors first reported a position in PROK in Q4 2023 and held it in 1 quarter. The position peaked at $226 in Q4 2023. 55 funds tracked by Wall St. Rank hold PROK as of Q1 2024.

  • LM Advisors reported no remaining ProKidney position as of Q1 2024 after selling out during the quarter.
  • LM Advisors sold 127 ProKidney shares in Q1 2024, an estimated $226.
  • LM Advisors first reported a position in ProKidney in Q4 2023 and held it in 1 quarter.
  • LM Advisors's ProKidney position peaked at $226 in Q4 2023.
  • 55 funds tracked by Wall St. Rank held ProKidney as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.